Coloplast: Awaiting a Strategy Update by the New CEO Amidst Persistent Headwinds

Research evidence excerpt

Coloplast: Awaiting a Strategy Update by the New CEO Amidst Persistent Headwinds

Deutsche Bank

Research

Rating Company Date

Hold Coloplast 18 May 2026

Forecast Change

Europe

Denmark

Reuters Bloomberg Exchange Ticker Price at 13 May 2026 (DKK) 399.30

COLOb.CO COLOB DC CPH COLOb

Price Target (DKK) 460.00

Healthcare

Medical Technologies & ADR ISIN 52-week range (DKK) 649.40393.90-

CLPBY US19624Y1010

Services

Awaiting a Strategy Update by the New

Valuation & Risks CEO Amidst Persistent Headwinds

Jan Koch, CFA

Takeaway summary Research Analyst

We believe the Coloplast investment case will continue to struggle following the +49-69-910-47428

recent profit warning. Several factors still weigh on the outlook, including potential

Falko Friedrichs

for an uptick in inflationary pressures and the recent further deterioration of the Research Analyst

Kerecis wound care business. Consequently, despite the stock's depressed +49-69-910-36270

valuation level, we remain on the sidelines and maintain our Hold rating.

Fynn Scherzler

Research Analyst

New CEO – Staying the Course and Believing in the Strategy +49-69-910-40764

Coloplast's new CEO, Gavin Wood, who commenced his role on May 1st, made his

Sachin Gadilingappa

first appearance on the conference call. He has focused his attention on talent

Research Associate

development, execution, and growth, underpinned by leveraging innovation and

the company's strong purpose. While it was premature for him to outline specific

strategic shifts – though some investors had hoped for this, given Coloplast's stock Key changes

performance – he stated his intention to "stay the course and believe in the strategy"

495.00 to

for the interim period, as he plans a 90-day "listening tour" to develop his TP 460.00 ↓ -7.1%

perspective on value drivers.